Leveron&Nexovas
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3862  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed9739    
    Printed135    
    Emailed0    
    PDF Downloaded117    
    Comments [Add]    
    Cited by others 4    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2016  |  Volume : 64  |  Issue : 3  |  Page : 405--410

MG-QoL-15 scores in treated myasthenia gravis: Experience from a university hospital in India


1 Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
2 Department of Biostatistics, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India

Correspondence Address:
Dr. Arun B Taly
Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore - 560 029, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.181542

Rights and Permissions

Background: Myasthenia gravis (MG) is an autoimmune disorder with a chronic fluctuating course. Quality of life (QoL) is affected by physical restrictions due to disease-related symptoms and effects of long-term treatment. Purpose: The purpose of this study was to assess QoL in a cohort of MG with stable disease course on optimal therapy. Materials and Methods: MG-QoL-15 was applied prospectively to 50 subjects of MG from India. Results: Mean MG-QoL-15 was 10.34 (standard deviation: 9.4; range: 0–32). Mean MG-QoL-15 scores for subjects with Myasthenia Gravis Foundation of America (MGFA) grades I, II, and III/IV were 3.54, 9.4, and 15.94, respectively. QoL scores correlated significantly with the MGFA grade. Age, gender, thymectomized status, thymoma, and steroid therapy did not affect QoL scores. All patients with MGFA grade I scored “0” or “1” in almost all items of MG-QoL-15. Seven and 11 patients with MGFA grades III/IV reported a significant affection (scores “3” or “4”) due to “trouble using my eyes” and “plan around MG,” respectively; and five subjects were “frustrated by MG.” None of the subjects, irrespective of their MGFA grade, reported significant difficulty in getting around public spaces due to MG, or had “trouble in performing personal grooming.” One subject each reported significant “trouble driving due to MG” or felt that “MG limits ability to enjoy hobbies and fun activities.” Conclusion: This is the first study from India to assess QoL in MG using MG-QoL-15. Increased disease severity was reflected in worse QoL. MG-QoL-15 is a simple, quick, and user-friendly tool. Longitudinal changes in the QoL scores may be required to determine its utility in the Indian context.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow